Grepid

Grepid is a prescription medication that contains the antiplatelet agent clopidogrel as its active ingredient. It is supplied as an oral dosage form, typically in tablet form, and is marketed in the European Union. As a P2Y12 receptor antagonist, Grepid works by irreversibly inhibiting platelet aggregation, helping to reduce the risk of clot‑related cardiovascular events. The medication is intended for use under medical supervision and is not available over the counter.

Grepid is prescribed for several antithrombotic indications where prevention of platelet‑driven clot formation is essential.

- Prevention of atherothrombotic events in patients with a prior myocardial infarction, ischemic stroke, or established peripheral arterial disease. - Secondary prevention after an acute coronary syndrome, including unstable angina or non‑ST‑segment elevation myocardial infarction. - Reduction of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) with stent placement. - Use in combination with aspirin for dual antiplatelet therapy when indicated by clinical guidelines.

The safety profile of Grepid includes a range of adverse reactions that vary in frequency and severity.

Common: - Minor bleeding such as gum bleeding, nosebleeds, or easy bruising. - Gastrointestinal discomfort, including nausea or dyspepsia. - Headache or dizziness. - Diarrhea or abdominal pain.

Serious: - Severe or uncontrolled bleeding, including intracranial hemorrhage. - Thrombotic thrombocytopenic purpura (TTP). - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Grepid, clinicians should evaluate several clinical factors to ensure safe use.

- Assess patient history for active bleeding or high bleeding risk. - Review liver function, as hepatic impairment may affect drug metabolism. - Consider renal function, especially in patients with severe chronic kidney disease. - Evaluate for known hypersensitivity to clopidogrel or any component of the formulation. - Use caution in patients receiving concurrent anticoagulants or antiplatelet agents. - Counsel women of childbearing potential about unknown pregnancy safety. - Discontinue before surgical procedures according to recommended timing.

Grepid can interact with other medicines, influencing either its antiplatelet effect or the effect of the co‑administered drug.

Avoid: - Concurrent use with strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole) that may reduce conversion to the active metabolite. - Combination with other antiplatelet agents (e.g., ticagrelor, prasugrel) that markedly increase bleeding risk. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants (warfarin, DOACs) when uncontrolled bleeding must be avoided.

Use with caution: - Co‑administration with proton pump inhibitors that have moderate CYP2C19 inhibition (e.g., pantoprazole). - Concomitant use of selective serotonin reuptake inhibitors (SSRIs) which may increase bleeding tendency. - Combination with glycoprotein IIb/IIIa inhibitors during PCI procedures.